Still Cloudy: CMS “Hopeful” Some Sunshine Data Collection Begins In 2013
CMS is still unable to provide certainty regarding the timeline for releasing a final rule implementing the Sunshine Act, Policy and Data Analysis Group Director Niall Brennan told a congressional roundtable on the issue Sept. 12.
You may also be interested in...
Physician Sunshine Rule Needs Longer Lead Time Before Implementation, PhRMA Says; Scope Challenged By CROs
The Pharmaceutical Research and Manufacturers of America seeks at least a six-month lead time before implementation in comments to CMS. The Association for Clinical Research Organizations takes issue with including payments for “legitimate” research in the rulemaking at all.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.
Strategy could improve chances of passage, offer politicians the opportunity to show the public they are doing something to address drug pricing.